

Appendix: Tables

1.	Sales January to December 2024 and 2023.....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023.....	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2024 vs. YTD December 2023	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan.....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International.....	10
9.	Roche Group consolidated income statement for the six months ended 31 December 2024	11
10.	Roche Group core results reconciliation – Full Year 2024	12
11.	Divisional core results reconciliation – Full Year 2024.....	13
12.	Roche Group consolidated balance sheet	14
13.	Roche Group consolidated statement of cash flows	15

1. Sales January to December 2024 and 2023

CHF millions	Twelve months ended 31 December		% change	
	2024	2023	At CER	In CHF
Pharmaceuticals Division	46,171	44,265	8	4
United States	24,774	23,259	9	7
Europe	8,832	8,306	8	6
Japan	2,874	3,745	-16	-23
International*	9,691	8,955	17	8
Diagnostics Division	14,324	14,451	4	-1
Roche Group	60,495	58,716	7	3

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

2. Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023

CHF millions	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023
Pharmaceuticals Div.	10,893	-2	10,921	2	11,716	9	11,620	10	11,914	12
United States	5,829	5	5,692	5	6,190	6	6,284	9	6,608	15
Europe	2,047	3	2,200	11	2,225	10	2,188	2	2,219	10
Japan	808	-50	649	-45	717	-3	717	1	791	1
International*	2,209	16	2,380	12	2,584	23	2,431	22	2,296	11
Diagnostics Division	3,770	4	3,478	2	3,733	8	3,516	6	3,597	-1
Roche Group	14,663	0	14,399	2	15,449	9	15,136	9	15,511	9

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2024 vs. YTD December 2023

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	6,744	9	4,819	5	1,306	14	-	-	619	29
Hemlibra	4,503	12	2,654	9	926	11	367	8	556	41
Vabysmo	3,864	68	2,940	57	622	128	125	40	177	168
Tecentriq	3,640	0	1,763	-7	863	4	380	0	634	23
Perjeta	3,616	1	1,345	3	646	-15	116	-40	1,509	15
Actemra/RoActemra	2,645	5	1,331	11	658	-14	309	9	347	19
Xolair	2,470	16	2,470	16	-	-	-	-	-	-
Kadcyla	1,998	7	765	3	564	-1	98	5	571	23
Phesgo	1,740	62	570	38	738	40	136	**	296	111
Evrystdi	1,631	18	588	19	572	14	93	10	378	25
Alecensa	1,548	7	525	15	284	-1	198	3	541	7
Herceptin	1,381	-11	265	-18	303	-13	14	-50	799	-6
MabThera/Rituxan	1,379	-13	842	-13	150	-15	17	-25	370	-10
Avastin	1,233	-17	383	-19	85	-11	197	-32	568	-10
Activase/TNKase	1,202	5	1,140	5	-	-	-	-	62	5
Polivy	1,121	39	568	70	192	13	198	-4	163	76
Gazyva	910	16	463	20	245	9	29	-15	173	23
Pulmozyme	455	4	303	2	73	-3	1	21	78	22
CellCept	399	7	23	-22	124	2	40	-3	212	17
Mircera	397	-3	-	-	42	-3	38	-23	317	1
Enspryng	311	30	94	39	30	67	146	5	41	209
Elevidys	189	-	-	-	-	-	-	-	189	-
Columvi	172	**	100	417	38	370	-	-	34	**

Xofluza	152	75	36	199	-	-	-	-	116	55
Rozlytrek	134	60	51	14	21	29	9	19	53	236
Lunsumio	71	25	51	4	19	148	-	-	1	**
Cotellic	41	-13	17	-21	11	0	-	-	13	-12
Luxturna	18	-59	18	-59	-	-	-	-	-	-
Piasky	16	-	-	-	1	-	15	-	-	-
Itovebi	8	-	8	-	-	-	-	-	-	-
Susvimo	4	44	4	44	-	-	-	-	-	-
Ronapreve	3	-99	-	-	3	-37	-	-100	-	-99
Pharma other	2,176	-23	638	-40	316	-13	348	-23	874	-8
Pharma total sales	46,171	8	24,774	9	8,832	8	2,874	-16	9,691	17

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023
Ocrevus	1,614	9	1,658	8	1,701	9	1,697	11	1,688	7
Hemlibra	1,035	9	1,040	8	1,103	6	1,137	14	1,223	21
Vabysmo	744	160	847	108	947	81	1,022	59	1,048	43
Tecentriq	975	5	865	1	933	2	905	0	937	-1
Perjeta	773	-11	936	-3	985	-1	888	2	807	9
Actemra/RoActemra	687	13	618	-2	658	8	672	7	697	4
Xolair	575	7	496	10	614	11	627	12	733	29
Kadcyla	480	13	483	3	516	9	495	7	504	9
Phesgo	303	58	388	70	411	52	445	55	496	72
Evrysdi	354	22	356	7	482	42	408	13	385	10
Alecensa	376	7	355	4	411	10	385	7	397	8
Herceptin	365	-14	364	-17	376	-4	323	-13	318	-10
MabThera/Rituxan	370	-15	351	-18	355	-15	317	-14	356	-2
Avastin	363	-15	324	-15	330	-18	289	-19	290	-17
Activase/TNKase	270	-1	296	4	297	-7	302	9	307	15
Polivy	232	74	250	81	263	34	304	24	304	34
Gazyva	196	12	213	16	232	15	225	8	240	25
Pulmozyme	110	-6	112	-6	113	2	104	4	126	18
CellCept	98	-8	94	0	103	9	86	-5	116	23
Mircera	108	4	96	0	77	-15	131	10	93	-9

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023
Ocrevus	289	11	310	8	329	15	322	11	345	21
Hemlibra	208	8	231	17	237	12	222	3	236	15
Vabysmo	91	406	138	224	149	153	167	104	168	88
Tecentriq	217	2	210	12	219	8	220	-3	214	0
Perjeta	161	-21	171	-19	170	-12	161	-19	144	-9
Actemra/RoActemra	192	-1	188	1	175	-8	145	-26	150	-21
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	131	-17	145	-2	143	0	140	-5	136	5
Phesgo	150	49	169	55	185	47	189	33	195	32
Evrysdi	135	39	137	27	149	16	149	13	137	3
Alecensa	72	1	72	3	73	-1	72	0	67	-5
Herceptin	82	-10	77	-17	77	-12	73	-16	76	-6
MabThera/Rituxan	40	-15	39	-20	38	-14	32	-29	41	6
Avastin	20	-43	21	-27	23	-14	19	-9	22	13
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	37	-21	54	42	32	-23	56	2	50	38
Gazyva	55	18	62	17	61	9	62	-1	60	11
Pulmozyme	19	-15	20	0	19	3	16	-11	18	-2
CellCept	28	-14	32	0	28	-9	21	-30	43	51
Mircera	10	-2	10	-8	11	-7	10	-4	11	8

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	92	5	79	2	92	4	88	4	108	22
Vabysmo	28	42	23	33	30	38	33	40	39	46
Tecentriq	106	3	86	-4	96	0	95	0	103	2
Perjeta	54	3	36	-19	30	-39	26	-48	24	-53
Actemra/RoActemra	79	3	68	5	78	9	79	11	84	11
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	25	-6	21	-4	25	8	25	7	27	10
Phesgo	4	-	19	-	31	-	38	-	48	*
Evrysdi	26	19	20	13	24	16	22	2	27	9
Alecensa	55	5	43	3	53	5	48	2	54	4
Herceptin	6	-31	4	-41	4	-48	3	-56	3	-57
MabThera/Rituxan	5	-15	4	-20	5	-26	3	-30	5	-22
Avastin	68	-31	51	-33	51	-34	47	-32	48	-28
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	60	55	44	2	48	-5	51	-9	55	-3
Gazyva	10	-4	6	-19	9	-14	6	-17	8	-10
Pulmozyme	1	-4	-	27	-	24	1	2	-	32
CellCept	11	-12	9	-10	9	-11	9	-7	13	13
Mircera	13	-22	9	-25	10	-22	9	-23	10	-23

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023
Ocrevus	133	22	168	28	141	27	146	23	164	37
Hemlibra	104	14	138	51	135	16	152	64	131	36
Vabysmo	31	**	36	397	47	281	47	180	47	63
Tecentriq	187	39	133	34	156	30	163	32	182	5
Perjeta	323	21	386	14	434	14	366	25	323	9
Actemra/RoActemra	70	-3	84	-15	88	32	94	52	81	26
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	135	91	131	19	153	27	137	20	150	25
Phesgo	46	196	74	165	63	75	72	87	87	129
Evrysdi	69	18	64	-29	161	169	91	8	62	-9
Alecensa	122	5	136	5	153	15	129	4	123	4
Herceptin	204	-12	216	-14	224	6	184	-6	175	-9
MabThera/Rituxan	99	2	104	-11	94	-12	89	-7	83	-11
Avastin	161	-4	153	3	156	-11	133	-14	126	-16
Activase/TNKase	17	-1	14	7	18	25	13	-16	17	5
Polivy	25	214	35	181	45	72	42	42	41	70
Gazyva	33	2	45	47	45	14	41	7	42	31
Pulmozyme	16	18	26	22	19	17	15	32	18	18
CellCept	51	-4	48	8	59	30	51	13	54	16
Mircera	85	11	77	6	56	-15	112	16	72	-9

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

9. Roche Group consolidated income statement for the six months ended 31 December 2024

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	46,171	14,324	-	60,495
Other revenue	1,871	29	-	1,900
Cost of sales	(9,150)	(7,133)	-	(16,283)
Research and development	(13,299)	(2,005)	-	(15,304)
Selling, general and administration	(7,533)	(3,257)	(4,106)	(14,896)
Other operating income and expense	(2,473)	(12)	(10)	(2,495)
Operating profit	15,587	1,946	(4,116)	13,417
Financing costs				(1,412)
Other financial income (expense)				(212)
Profit before taxes				11,793
Income taxes				(2,606)
Net income				9,187
Attributable to				
- Roche shareholders				8,277
- Non-controlling interests				910
Earnings per share and non-voting equity security				
Basic (CHF)				10.39
Diluted (CHF)				10.31

10. Roche Group core results reconciliation – Full Year 2024

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	60,495	-	-	-	-	-	-	-	-	60,495
Other revenue	1,900	-	-	-	-	-	-	-	-	1,900
Cost of sales	(16,283)	142	385	358	-	-	-	-	-	(15,398)
Research and development	(15,304)	889	330	1,043	-	-	-	-	-	(13,042)
Selling, general and administration	(14,896)	1,096	21	21	-	-	-	-	-	(13,758)
Other operating income and expense	(2,495)	(236)	-	3,209	72	76	-	-	-	626
Operating profit	13,417	1,891	736	4,631	72	76	-	-	-	20,823
Financing costs	(1,412)	-	-	-	7	7	-	-	-	(1,398)
Other financial income (expense)	(212)	-	-	-	-	-	-	-	-	(212)
Profit before taxes	11,793	1,891	736	4,631	79	83	-	-	-	19,213
Income taxes	(2,606)	(389)	(12)	(226)	(12)	(16)	-	-	59	(3,202)
Net income	9,187	1,502	724	4,405	67	67	-	-	59	16,011
Attributable to										
- Roche shareholders	8,277	1,489	722	4,400	67	67	-	-	59	15,081
- Non-controlling interests	910	13	2	5	-	-	-	-	-	930
EPS - diluted (CHF)	10.31	1.86	0.90	5.50	0.08	0.08	-	-	0.07	18.80

11. Divisional core results reconciliation – Full Year 2024

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	46,171	-	-	-	-	-	-	46,171
Other revenue	1,871	-	-	-	-	-	-	1,871
Cost of sales	(9,150)	89	246	358	-	-	-	(8,457)
Research and development	(13,299)	838	325	1,040	-	-	-	(11,096)
Selling, general and administration	(7,533)	470	6	21	-	-	-	(7,036)
Other operating income and expense	(2,473)	(236)	-	3,209	43	18	-	561
Operating profit	15,587	1,161	577	4,628	43	18	-	22,014
Diagnostics								
Sales	14,324	-	-	-	-	-	-	14,324
Other revenue	29	-	-	-	-	-	-	29
Cost of sales	(7,133)	53	139	-	-	-	-	(6,941)
Research and development	(2,005)	51	5	3	-	-	-	(1,946)
Selling, general and administration	(3,257)	106	15	-	-	-	-	(3,136)
Other operating income and expense	(12)	-	-	-	29	55	-	72
Operating profit	1,946	210	159	3	29	55	-	2,402
Corporate								
Selling, general and administration	(4,106)	520	-	-	-	-	-	(3,586)
Other operating income and expense	(10)	-	-	-	-	3	-	(7)
Operating profit	(4,116)	520	-	-	-	3	-	(3,593)

12. Roche Group consolidated balance sheet

in millions of CHF	31 December 2024	31 December 2023	31 December 2022
Non-current assets			
Property, plant and equipment	22,557	21,724	23,075
Right-of-use assets	1,183	1,215	1,133
Goodwill	7,876	9,390	10,820
Intangible assets	17,303	14,828	9,685
Deferred tax assets	8,569	6,882	6,427
Defined benefit plan assets	2,256	1,019	957
Other non-current assets	2,021	1,964	2,238
Total non-current assets	61,765	57,022	54,335
Current assets			
Inventories	7,606	7,749	8,605
Accounts receivable	11,297	11,021	11,606
Current income tax assets	415	344	313
Other current assets	3,401	3,130	3,525
Marketable securities	10,342	5,134	4,776
Cash and cash equivalents	6,975	5,376	4,991
Assets held for sale	0	692	0
Total current assets	40,036	33,446	33,816
Total assets	101,801	90,468	88,151
Non-current liabilities			
Long-term debt	(30,722)	(24,809)	(21,391)
Net deferred tax liabilities	(832)	(593)	(645)
Defined benefit plan liabilities	(4,381)	(4,379)	(4,561)
Provisions	(1,079)	(1,059)	(1,111)
Other non-current liabilities	(1,603)	(1,541)	(1,189)
Total non-current liabilities	(38,617)	(32,381)	(28,897)
Current liabilities			
Short-term debt	(3,932)	(4,400)	(3,960)
Current income tax liabilities	(2,923)	(2,257)	(3,187)
Provisions	(1,726)	(1,684)	(2,248)
Accounts payable	(4,894)	(4,325)	(4,556)
Other current liabilities	(13,548)	(12,150)	(13,288)
Liabilities directly associated with assets held for sale	0	(8)	0
Total current liabilities	(27,023)	(24,824)	(27,239)
Total liabilities	(65,640)	(57,205)	(56,136)
Total net assets	36,161	33,263	32,015
Equity			
Capital and reserves attributable to Roche shareholders	31,767	29,315	27,992
Equity attributable to non-controlling interests	4,394	3,948	4,023
Total equity	36,161	33,263	32,015

13. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2024	FY 2023
Cash flows from operating activities		
Cash generated from operations	24,332	22,617
(Increase) decrease in net working capital	1,161	(1,107)
Payments made for defined benefit plans	(661)	(743)
Utilisation of provisions	(1,012)	(1,052)
Other operating cash flows	1	-
Cash flows from operating activities, before income taxes paid	23,821	19,715
Income taxes paid	(3,727)	(3,620)
Total cash flows from operating activities	20,094	16,095
Cash flows from investing activities		
Purchase of property, plant and equipment	(3,529)	(3,742)
Purchase of intangible assets	(1,480)	(907)
Disposal of property, plant and equipment	61	173
Disposal of intangible assets	-	-
Disposal of products	376	558
Business combinations and asset acquisitions	(3,119)	(6,220)
Divestment of subsidiaries	1	1
Interest and dividends received	232	168
Sales of marketable securities	198	125
Purchases of marketable securities	(112)	(87)
Sales (purchases) of money market instruments and time accounts over three months, net	(5,084)	(745)
Other investing cash flows	14	33
Total cash flows from investing activities	(11,393)	(10,643)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	7,915	8,167
Redemption and repurchase of bonds and notes	(3,095)	(1,751)
Increase (decrease) in commercial paper	(709)	(806)
Increase (decrease) in other debt	(292)	175
Hedging and collateral arrangements	30	155
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(1,145)	(770)
Principal portion of lease liabilities paid	(350)	(339)
Dividends paid	(8,043)	(7,926)
Equity-settled equity compensation plans, net of transactions in own equity	(1,130)	(1,144)
Other financing cash flows	-	-
Total cash flows from financing activities	(6,819)	(4,239)
Net effect of currency translation on cash and cash equivalents	(283)	(828)
Increase (decrease) in cash and cash equivalents	1,599	385
Cash and cash equivalents at beginning of period	5,376	4,991
Cash and cash equivalents at end of period	6,975	5,376